Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

Recent IBD Deals

1. Janssen, Theravance ink GI pact worth up to $1B

“Janssen and Theravance Biopharma are teaming up to develop a JAK inhibitor for inflammatory bowel disease. Theravance will pick up $100 million up front, with the potential to earn another $900 million in milestone payments and royalties.”

“Under the agreement, Theravance will conduct a phase 2 study of the candidate, TD-1473, in Crohn’s disease, as well as a phase 2b/3 induction and maintenance study in ulcerative colitis, both slated to start this year. If all goes well, Janssen may pull the trigger on an exclusive license agreement for the program and take the lead on developing the drug in Crohn’s, according to a statement.”

“If the drug is approved, Janssen will be responsible for ex-U.S. marketing, with Theravance receiving tiered royalties, while the pair has the option of co-commercializing within the U.S. They will also split profits in the U.S., as well as development costs, with Janssen picking up 67% of the tab.”

https://www.fiercebiotech.com/biotech/janssen-theravance-ink-gi-pact-worth-up-to-1b

2. Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug (preclinical)

"Johnson & Johnson has landed rights to Protagonist Therapeutics’ preclinical Crohn’s disease asset PTG-200. The deal gives J&J a stake in an oral interleukin-23 (IL-23) receptor antagonist in return for $50 million upfront and up to $940 million in milestones."

"The asset is due to enter the clinic this year. Protagonist will run and fund the trial with J&J taking over—and covering 80% of the costs—once it advances to phase 2. Beyond this, a series of major paydays await Protagonist. J&J will pay Protagonist $125 million if it moves the drug into phase 2b and a further $200 million if it sticks with the asset after getting a look at data from the trial. The rest of the cash is tied to regulatory and sales milestones."

http://www.fiercebiotech.com/biotech/j-j-commits-990m-to-land-protagonist-s-oral-crohn-s-drug

3. Celgene Completes Acquisition of Receptos, Advancing Leadership in Immune-Inflammatory Diseases

"Celgene Corporation (CELG) today announced it has closed its acquisition of Receptos, Inc. Receptos stockholders received $232.00 per share in cash, for a total of approximately $7.2 billion, net of cash acquired."

http://www.fiercepharma.com/pharma/celgene-completes-acquisition-of-receptos-advancing-leadership-immune-inflammatory-diseases

4. Celgene enters deal potentially worth over $2.5 billion for Nogra Pharma's Crohn's disease drug

"Celgene announced a global licensing deal Thursday potentially valued at more than $2.5 billion to develop and market Nogra Pharma's experimental drug GED-0301 for moderate-to-severe Crohn's disease and other indications."

https://www.firstwordpharma.com/node/1205296?tsid=1

5. Gilead swoops down on Galapagos JAK1 candidate filgotinib in $2.075B deal

"Gilead Sciences Inc., is stepping in where Abbvie Inc. stepped out, laying down a whopping $725 million, with up to $1.35 billion more to come in milestones, for rights to Galapagos NV's Janus kinase 1 (JAK1)-selective inhibitor filgotinib (GLPG0634)."

http://www.bioworld.com/content/gilead-swoops-down-galapagos-jak1-candidate-filgotinib-2075b-deal

6. Salix Expands in GI Drugs and Beyond with $2.6B Santarus Acquisition

"Salix Pharmaceuticals said it will acquire Santarus for about $2.6 billion, in an all-cash deal that expands the buyer’s gastrointestinal (GI) drug portfolio and extends its product offerings into primary care and diabetes."

http://www.genengnews.com/gen-news-highlights/salix-expands-in-gi-drugs-and-beyond-with-2-6b-santarus-acquisition/81249089